Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.578 USD | +0.64% | -0.82% | +6.39% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.39% | 120M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+3.03% | 22.39B | |
-11.32% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024